Case report

Central retinal artery occlusion secondary to Barlow's disease

Carl S. Wilkins, Katherine McCabe, Avnish Deobhakta, James Chelnis

Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA
Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 East 14th Street, New York, NY 10003, USA

1. Introduction

Central retinal artery occlusion (CRAO) is a well-known ophthalmic emergency, analogous to a stroke of the eye. CRAO is often a harbinger of further cardiovascular morbidity and mortality, and thus merits an emergent medical evaluation beyond ophthalmic care. Though relatively uncommon with an incidence of roughly 1 in every 100,000 people, CRAO from cholesterol or thrombotic emboli has been widely described in relation to carotid, cardiac, and hypercoagulable states. It is exceedingly uncommon in young patients, with few published cases in the literature.

Young patients may be more likely to have systemic or cardiac source of CRAO when compared to adults with carotid atherosclerotic disease. In patients with an embolic cardiac source, rapid diagnosis and management must be accomplished to avoid further embolization to cerebral or more distal arterial locations. We report a case of CRAO likely from a calcific embolus in a young woman as the presenting feature of Barlow's disease. The new diagnosis led to prompt surgical intervention for this severe form of mitral valve prolapse and minimization of her risk of future embolic events.

2. Case report

A 29-year-old woman presented to the eye emergency department with sudden onset of painless visual loss in her left eye. Her past medical history was remarkable for severe premature ventricular contractions (PVC), for which she underwent cardiac catheterization and ablation several years prior. She had no significant ocular history, nor did she report history of auto-immune disorder, deep vein thrombosis (DVT), or coagulopathy. She complained of occasional palpitations, and denied any flashes, floaters, amaurosis fugax, photophobia, temporal headaches, jaw claudication, rashes, or joint pains.

Upon initial examination, her best corrected visual acuity (BCVA) was 20/20 in her right eye (OD), and hand motion (HM) in her left eye (OS). She was found to have a 4+ afferent pupillary defect (APD) OS. Her intraocular pressures were within normal limits. Funduscopic examination was unremarkable OD and revealed cherry-red spot with surrounding retinal pallor, as well as 1+ optic nerve head edema OS. She was diagnosed with central retinal artery occlusion (CRAO) OS (Fig. 1), and emergently transferred to tertiary care inpatient center for advanced imaging and possible intravascular intervention.

After arrival, she was evaluated by the stroke team and taken for advanced imaging and possible intravascular intervention.
emergent CT scan of head and neck as well as CT angiogram. All imaging studies were unremarkable, including bilateral patency of the carotid arteries with 0% observed stenosis. The decision was made to take the patient to interventional radiology for cerebral angiogram, and intra-arterial thrombolysis (IAT) via the left ophthalmic artery. At that point, the patient was ~10 hours from onset of symptoms. Pre- and post-procedure cerebral angiography did not reveal any gross areas of ischemia. The patient tolerated the intervention well and was transferred to the stroke unit post-operatively.

On post-procedure day one her BCVA was stable at 20/20 OD and hand motion OS, with marked APD and stable funduscopic examination. Due to the absence of carotid pathology, she underwent echocardiogram which revealed a calcified mitral valve with pedunculated left atrial mass arising from a mitral valve leaflet (Fig. 2). A small septum secundum atrial septal defect (ASD) was also noted. Upon discussion with the patient’s outside cardiologist, the mass appeared to have been a relatively new development which was not seen on catheterization several years prior. The cardiologist made note of a calcified mitral valve at that time, though subsequent work up for hypercalcemia was negative. The patient has no history of rheumatic fever, is from the United States, and has not travelled extensively. Her rheumatologic and hematologic evaluations were both unremarkable. She underwent ultrasonography of bilateral lower extremities which was negative for DVT.

Upon consultation with cardiothoracic surgery, decision was made to take the patient to the operating room for resection of cardiac mass, mitral valve repair, and ASD repair. Intra-operatively, the patient was found to have Barlow’s disease - a condition affecting the mitral valve - characterized by excessive myxomatous tissue formation, annular calcification, and severe billowing with prolapse of the mitral valve. The patient tolerated the procedure well, was transferred to the cardiothoracic ICU, recovered well on the cardiac floor, and was discharged home.

At post-op week 1 follow-up (10 days post-CRAO OS), the patient’s BCVA remained at 20/20 and HM. An OCT macula was obtained OU which demonstrated increased thickness of the retinal nerve fiber layer (RNFL) OS relative to OD. Funduscopic exam demonstrated resolution of papillitis, with continued RNFL edema. At month 1 follow-up, the patient’s vision was stable at HM OS. Repeat OCT macula demonstrated decrease in RNFL thickness OS (Fig. 3). She did not show any signs of neovascularization at 1 month. After discussion of risks and benefits of intravitreal anti-VEGF therapy, the patient underwent intravitreal injection with bevacizumab OS. The patient’s vision remained at HM OS at subsequent follow-up.

3. Discussion

CRAO is a vision-threatening condition in which acute ischemia of the retina develops after interruption of blood flow through the central retinal artery (CRA). Typical presentation of a CRAO involves sudden, painless visual loss which is usually unilateral and often occurs in patients with known cardiovascular risk factors such as hypertension and diabetes mellitus.1 BCVA in patients with CRAO is often 20/400 or worse.1 In 26–50% of patients, a patent cilioretinal artery has been reported, which, in a fortunate subpopulation, preserves visual acuity to varying degrees depending on its contribution to papillo-macular perfusion.1,3,4 Without this variation, visual loss is often profound. In a review of 244 cases (260 eyes) it was found that recovery from an average of count fingers vision was best in transient non-arteritic CRAO (83%), and worst in permanent non-arteritic CRAO (22%).5 This finding suggests that the retina, while the most demanding metabolic tissue in the body, is nevertheless able to withstand short-lived ischemia. Previous animal investigations have demonstrated a retinal ischemic tolerance time of 105 minutes following total occlusion of the CRA.6

Most CRAOs are caused by cholesterol emboli (74%), with platelet-thrombin emboli and calcium constituting the remaining proportion.7 In adults, emboli generally arise secondary to atherosclerosis from diabetes mellitus and hypertension, as well as from malignancy.1,4,5,8 In younger patients, hypercoagulability such as factor V leiden deficiency, sickle cell disease, or anti-phospholipid syndrome are major causes.1 Arrhythmias, such as atrial fibrillation, predispose patients to platelet emboli.9 Cardiac valvular disease such as rheumatic valvular degeneration or inherited abnormalities, such as in our patient, may serve as a nidus for embolus generation.4,8,9 One retrospective study by Greven et al. found 21 patients younger than 40 years of age with retinal artery occlusions, of which the majority (71%) were branch RAO, and 25% were CRAO.2 Among these patients, 19% were found to have some form of cardiac valvular disease. Paradoxical embolus, though a rare cause of CRAO, has been reported, and must be investigated with ultrasonography of the lower extremities in patients with patent foramen ovale.5,10

In our patient, echocardiography demonstrated a classic triad for Barlow’s disease, a condition characterized by myxomatous proliferation of the mitral valve, calcification of the annulus, and mitral valve prolapse.1 Due to discrete mass on TEE, presumed diagnosis of papillary fibroelastoma was made until surgical specimen were obtained, which demonstrated calcified mass secondary to fibromyxomatous proliferation. Branch retinal artery occlusion from a mitral valve
papillary fibroelastoma has been previously reported in a young female. Several cases of mitral valve prolapse, whether in Barlow’s or other conditions, have been reported causes of retinal artery occlusions. In young patients present with negative medical histories, carotid duplex and echocardiography (TTE or TEE) must be performed to identify sources of embolism, along with coagulopathy and perhaps vasculitis workups. In addition to mitral valve abnormality, our patient had a small septum secundum ASD, which serves as a possible pathway for paradoxical embolus. Ultrasonography of bilateral lower extremities was negative for DVT, making paradoxical embolus unlikely. CRAO in a young, otherwise healthy person must signal the clinician to the presence of a previously undiagnosed vascular, cardiac, or systemic disorder. A failure to identify these issues may result in further morbidity and mortality. Furthermore, this case may demonstrate need for serial examination and close follow-up with non-ophthalmic specialists when abnormalities such as valvular calcifications are present. In our patient, failure to detect the cardiac source of embolus may have resulted in devastating neurologic consequences.

Treatment for CRAO remains controversial. Previous studies have investigated the use of systemic nitrate therapy, ocular massage, intravenous steroids, anterior chamber paracentesis, and tPA administration. Results from multiple studies have been varied. A case series of 37 patients with CRAO who received intra-arterial thrombolysis (IAT) demonstrated improved BCVA in those patients compared to controls. One large meta-analysis identified 100 patients who received local intra-arterial fibrinolysis and found equivocal benefit, though all studies included were retrospective and extended the inclusion period beyond that of reversible ischemia. The EAGLE trial, a prospective study of IAT and CRAO, was terminated early after interval analysis revealed no difference between IAT and conventional treatments, with more adverse events in the IAT group. Most patients within the IAT group received IAT from 5 to 15 hours after onset of symptoms, possibly too late to demonstrate efficacy. One major barrier is inaccessibility of most hospitals to neuro-interventional care. As was with our patient, even with rapid diagnosis, transfer to tertiary care facility with that capability, and “time to table”, presents a common logistical barrier.

Due to the varied compositions of retinal emboli, unclear CRAO “golden window”, and inability to predict which patients may benefit from such interventional treatments, a randomized controlled trial aiming for already well-established stroke windows (3-4.5 hours) may help clarify the role of IAT in CRAO. Though failing to demonstrate overall superiority, Chen et al., demonstrated improved outcomes in subgroup analysis with intravenous tPA given within 6 hours of symptoms onset. Given the devastating nature of many CRAOs, even minor benefit would be meaningful progress towards visual recovery for patients as one additional line of vision may halve the patient’s visual angle. We hypothesize that our patient’s lack of response to IAT was due to either treatment outside of the “golden window”, cholesterol or calcium composition of the occlusion, or both.

We present a rare case of a patient with isolated, unilateral CRAO from mitral valve prolapse secondary to Barlow’s disease. Due to the systemic implications of CRAO sources, as well as possibility of further visual loss, clinicians should be aggressive in work-up of patients presenting in such a fashion. In young, otherwise healthy patients, a full carotid, cardiac, auto-immune, and hematologic work-up may be necessary in order to identify the cause of CRAO. Rapid identification of the correct etiology will enable these patients to obtain the proper medical or surgical intervention(s), and help to prevent additional morbidity and mortality among these patients.

![Fig. 3. OCT macula of left eye at 10 days (top) and 1 month (bottom), demonstrating hyper-reflective retinal nerve fiber layer and increased thickness OS, indicative of edema and neurosensory dysfunction secondary to ischemia. Decreased macular thickness is evident at 1 month follow-up.](image)
4. Patient consent

All patient identifiers and information contained within this manuscript have been made anonymous in compliance with institutional and HIPAA policies. No identifiable patient information or images are included in this report, therefore, patient consent to publish was not obtained.

Funding

The authors have received no funding or grant support for this manuscript.

Conflicts of interest

The following authors have no financial disclosures: CSW, KM, AD, JC.

Authorship

All authors attest that they meet the current ICMJE criteria for authorship.

Acknowledgments

None.

References

1. Varma DD, Cugati S, Lee AW, Chen CS. A review of central retinal artery occlusion: presentation and clinical management. *Eur. 2013;27:688–697.
2. Green CM, Slusher MM, Weaver RG. Retinal arterial occlusions in young adults. *Am J Ophthalmol. 1995;120(6):776–783.
3. Brown GC, Shields JA. Cilioretinal arteries and retinal arterial occlusion. *Arch Ophthalmol. 1979;97(1):84–92.
4. Hayreh SS. Acute retinal arterial occlusive disorders. *Prog Retin Eye Res. 2011;30:359–394.
5. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. *Am J Ophthalmol. 2005;140(3):376–391.
6. Hayreh SS, Korder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. *Ophthalmology. 1980;87:75–78.
7. Arruga J, Sanders MD. Ophthalmologic findings in 70 patients with with evidence of retinal embolism. *Ophthalmology. 1982;89:1336–1337.
8. Callizo J, Feltgen N, Pastenberg S, et al. Cardiovascular risk factors in central retinal artery occlusion: results of a prospective and standardized medical examination. *Ophthalmology. 2015;122:1881–1888.
9. Caltrider ND, Irvine AR, Kline HI, Rosenblatt A. Retinal emboli in patients with mitral valve prolapse. *Am J Ophthalmol. 1980 Oct 1;90(4):534–539.
10. Ho IV, Spada R. Central retinal artery occlusion associated with a patent foramen ovale. *Retina. 2007;27:259–260.
11. Melnitchouk SI, Seeburger J, Kaeding MF, Misfeld M, Mohr FW, Borger MA. Barlow’s mitral valve disease: results of conventional and minimally invasive repair approaches. *Ann Cardiothorac Surg. 2013;2(6):768–773.
12. Zamora RL, Adelberg DA, Berger AS, Huetner P, Kaplan HJ. Branch retinal artery occlusion caused by a mitral valve papillary fibroelastoma. *Am J Ophthalmol. 1995;119:25–119329.
13. Shin YT, Kim JH, Park DH, Shin JP, Kim IT. Central retinal artery occlusion by left atrial myxoma. *Kor J Ophthalmol. 2017;31(1):88–89.
14. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. *Am J Ophthalmol. 1999;128(6):733–738.
15. Schumacher M, Schmidt D, Jurkies B, et al. EAGLE-study group. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. *Ophthalmology. 2010;117(7):1367–1375.
16. Beatty S, Au Eong KG. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. *Br J Ophthalmol. 2000;84:914–916.
17. Schmidt DP, Schulte-Monting J, Schumacher M. Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. *Am J Neuroradiol. 2002;23:1301–1307.
18. Arnold M, Koerner U, Remonda L, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. *J Neurol Neurosurg Psychiatry. 2005;76:196–199.
19. Chen CS, Lee AW, Campbell B, et al. Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion. *Stroke. 2011;42:2229–2234.